Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis

• Published in: Expert opinion on therapeutic targets Vol. 20; no. 3; p. 287
• Main Authors: Rainville, Nicole, Jachimowicz, Edward, Wojchowski, Don M
• Format: Journal Article
• Language: English
• Published: England 03.03.2016
• Subjects: Anemia - drug therapy; Anemia - etiology; Anemia - physiopathology; Animals; Drug Design; Erythropoiesis - drug effects; Erythropoietin - pharmacology; Erythropoietin - therapeutic use; Hematinics - adverse effects; Hematinics - pharmacology; Hematinics - therapeutic use; Humans; Molecular Targeted Therapy; Receptors, Erythropoietin - drug effects; Receptors, Erythropoietin - metabolism; Recombinant Proteins; erythropoietin receptor; hypoxia inducible factors; prolyl hydroxylases; erythroid models; erythropoiesis; Spi2a; anemia; erythroferrone; erythropoiesis-stimulating agents; protein tyrosine phosphatases; erythropoietin; janus kinase 2

Recombinant human erythropoietin (rhEPO) is a first-line therapeutic for the anemia of chronic kidney disease, cancer chemotherapy, AIDS (Zidovudine therapy), and lower-risk myelodysplastic syndrome. However, rhEPO frequently elevates hypertension, is costly, and may affect cancer progression. Poten...